Vanguard Group
ABCL icon

Vanguard Group’s AbCellera Biologics ABCL Stock Holding History

Vanguard Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,112
Closed -$74.9K – 4450
2023
Q4 		$74.9K Buy
+13,112
New +$60.8K ﹤0.01% 4337
2023
Q2 		– Sell
-989,154
Closed -$7.46M – 4549
2023
Q1 		$7.46M Buy
989,154
+12,597
+1% +$114K ﹤0.01% 3105
2022
Q4 		$9.89M Buy
976,557
+97,665
+11% +$1.13M ﹤0.01% 2950
2022
Q3 		$8.69M Sell
878,892
-15,282
-2% -$168K ﹤0.01% 3017
2022
Q2 		$9.52M Buy
+894,174
New +$7.57M ﹤0.01% 3014

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group's ABCL Position: Q1 2024 in Review

Vanguard Group sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 13,112 shares — an estimated $74.9K sold.

Vanguard Group first reported a position in ABCL in Q2 2022 and held it in 5 quarters. The position peaked at $9.89M in Q4 2022. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • Vanguard Group reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 13,112 AbCellera Biologics shares in Q1 2024, an estimated $74.9K.
  • Vanguard Group first reported a position in AbCellera Biologics in Q2 2022 and held it in 5 quarters.
  • Vanguard Group's AbCellera Biologics position peaked at $9.89M in Q4 2022.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.